Silymarin in the Treatment of Patients With Primary Biliary Cirrhosis With a Suboptimal Response to Ursodeoxycholic Acid

Angulo, Paul

doi:10.1053/jhep.2000.18663

Cited by 82 publications

(58 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, total antioxidant activity of the serum increases in patients with PBC [11]. Antioxidant drugs silymarin and catergen produced no positive therapeutic effect in PBC patients [5].…”

Section: Resultsmentioning

confidence: 97%

Primary biliary cirrhosis and coronary atherosclerosis: Protective antioxidant effect of bilirubin

et al. 2008

View full text Add to dashboard Cite

Increased concentration of lipid peroxidation products in patients with primary biliary cirrhosis is related to elevation of serum lipid content, but not to activation of lipid peroxidation. Hyperbilirubinemia in patients with primary biliary cirrhosis is accompanied by a decrease in the concentration of lipid peroxidation products and increase in antioxidant activity of blood serum. Antioxidants play a major role in the prevention of atherosclerosis. We hypothesized that the absence of increased risk of atherosclerosis in patients with primary biliary cirrhosis is due to inhibition of lipid peroxidation in blood serum by antioxidant compound bilirubin.

show abstract

Section: Resultsmentioning

confidence: 97%

Primary biliary cirrhosis and coronary atherosclerosis: Protective antioxidant effect of bilirubin

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Accordingly, antioxidant therapy represents a potential strategy to prevent liver injury and fibrosis. Previous studies show that antioxidants, including N-acetylcysteine, vitamin E, silymarin, and quercetin, decrease lipid peroxidation and partially ameliorate liver injury after BDL, but the effects of antioxidants on fibrosis remain controversial (4,33,35,36,47).…”

Section: Discussionmentioning

confidence: 99%

Polyphenols fromCamellia sinenesisattenuate experimental cholestasis-induced liver fibrosis in rats

Zhong¹,

Froh²,

Lehnert³

et al. 2003

American Journal of Physiology-Gastrointestinal and Liver Physi

View full text Add to dashboard Cite

Accumulation of hydrophobic bile acids during cholestasis leads to generation of oxygen free radicals in the liver. Accordingly, this study investigated whether polyphenols from green tea Camellia sinenesis, which are potent free radical scavengers, decrease hepatic injury caused by experimental cholestasis. Rats were fed a standard chow or a diet containing 0.1% polyphenolic extracts from C. sinenesis starting 3 days before bile duct ligation. After bile duct ligation, serum alanine transaminase increased to 760 U/l after 1 day in rats fed a control diet. Focal necrosis and bile duct proliferation were also observed after 1–2 days, and fibrosis developed 2–3 wk after bile duct ligation. Additionally, procollagen-α1(I) mRNA increased 30-fold 3 wk after bile duct ligation, accompanied by increased expression of α-smooth muscle actin and transforming growth factor-β and the accumulation of 4-hydroxynenonal, an end product of lipid peroxidation. Polyphenol feeding blocked or blunted all of these bile duct ligation-dependent changes by 45–73%. Together, the results indicate that cholestasis due to bile duct ligation causes liver injury by mechanisms involving oxidative stress. Polyphenols from C. sinenesis scavenge oxygen radicals and prevent activation of stellate cells, thereby minimizing liver fibrosis.

show abstract

“…However, this same dose of silymarin did not impact on the survival of patients with alcoholic cirrhosis in another large, placebocontrolled trial [22]. We did not find any evidence of benefit in patients with primary biliary cirrhosis treated with the same dose of silymarin for 1 year [23]. In clinical studies carried out to date, the most common daily dose of silymarin was 420 mg.…”

Section: Discussionmentioning

confidence: 54%

Silymarin in the Treatment of Patients with Primary Sclerosing Cholangitis: An Open-Label Pilot Study

et al. 2007

View full text Add to dashboard Cite

No effective medical therapy is available for patients with primary sclerosing cholangitis (PSC). We evaluated the safety and estimated the efficacy of silymarin in patients with PSC in a pilot study. Thirty patients with PSC were enrolled. Silymarin, 140 mg orally three times daily, was given for 1 year. A statistically significant improvement in serum alkaline phosphatase activity (1131 +/- 216 vs. 861 +/- 139, P = 0.007), and aspartate aminotransferase (AST) levels (116 +/- 15 vs. 83 +/- 11, P = 0.01) occurred with treatment. Serum bilirubin levels were not significantly affected by the treatment, while serum albumin and the Mayo risk score remained essentially unchanged. Overall, 34% of patients had a positive response to silymarin as defined by > or =50% improvement or normal status in liver tests. The results of this pilot study warrant further evaluation of silymarin in patients with PSC in a large-scale, controlled trial.

show abstract

Silymarin in the Treatment of Patients With Primary Biliary Cirrhosis With a Suboptimal Response to Ursodeoxycholic Acid

Cited by 82 publications

References 32 publications

Primary biliary cirrhosis and coronary atherosclerosis: Protective antioxidant effect of bilirubin

Primary biliary cirrhosis and coronary atherosclerosis: Protective antioxidant effect of bilirubin

Polyphenols fromCamellia sinenesisattenuate experimental cholestasis-induced liver fibrosis in rats

Silymarin in the Treatment of Patients with Primary Sclerosing Cholangitis: An Open-Label Pilot Study

Contact Info

Product

Resources

About